Site-specific glycoproteomic characterization of ES-62 : the major secreted product of the parasitic worm Acanthocheilonema viteae
North, Simon J and Botchway, Kwamina and Doonan, James and Lumb, Felicity E and Dell, Anne and Harnett, William and Haslam, Stuart M (2019) Site-specific glycoproteomic characterization of ES-62 : the major secreted product of the parasitic worm Acanthocheilonema viteae. Glycobiology, 29 (8). pp. 562-571. ISSN 0959-6658 (https://doi.org/10.1093/glycob/cwz035)
Preview |
Text.
Filename: North_etal_Glycobiology_2019_Site_specific_glycoproteomic_characterization_of_ES_62.pdf
Final Published Version License: Download (12MB)| Preview |
Abstract
ES-62 is the major secreted product of the parasitic filarial nematode Acanthocheilonema viteae and has potent anti-inflammatory activities as a consequence of posttranslational decoration by phosphorylcholine (PC). Previously, we showed that ES-62's PC was attached to N-linked glycans, and using fast atom bombardment mass spectrometry, we characterized the structure of the glycans. However, it was unknown at this time which of ES-62's four potential N-glycosylation sites carries the PC-modified glycans. In the present study, we now employ more advanced analytical tools-nano-flow liquid chromatography with high-definition electrospray mass spectrometry-to show that PC-modified glycans are found at all four potential N-glycosylation sites. Also, our earlier studies showed that up to two PC groups were detected per glycan, and we are now able to characterize N-glycans with up to five PC groups. The number per glycan varies in three of the four glycosylation sites, and in addition, for the first time, we have detected PC on the N-glycan chitobiose core in addition to terminal GlcNAc. Nevertheless, the majority of PC is detected on terminal GlcNAc, enabling it to interact with the cells and molecules of the immune system. Such expression may explain the potent immunomodulatory effects of a molecule that is considered to have significant therapeutic potential in the treatment of certain human allergic and autoimmune conditions.
ORCID iDs
North, Simon J, Botchway, Kwamina, Doonan, James ORCID: https://orcid.org/0000-0001-6933-4840, Lumb, Felicity E ORCID: https://orcid.org/0000-0001-9742-5125, Dell, Anne, Harnett, William ORCID: https://orcid.org/0000-0001-9545-9401 and Haslam, Stuart M;-
-
Item type: Article ID code: 69736 Dates: DateEvent30 August 2019Published16 May 2019Published Online10 May 2019AcceptedSubjects: Medicine > Therapeutics. Pharmacology Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 10 Sep 2019 14:12 Last modified: 11 Nov 2024 12:26 Related URLs: URI: https://strathprints.strath.ac.uk/id/eprint/69736